• Je něco špatně v tomto záznamu ?

Molecular Profiling of Salivary Gland Intraductal Carcinoma Revealed a Subset of Tumors Harboring NCOA4-RET and Novel TRIM27-RET Fusions: A Report of 17 cases

A. Skálová, T. Vanecek, E. Uro-Coste, JA. Bishop, I. Weinreb, LDR. Thompson, S. de Sanctis, M. Schiavo-Lena, J. Laco, C. Badoual, T. Santana Conceiçao, N. Ptáková, M. Baněčkova, M. Miesbauerová, M. Michal,

. 2018 ; 42 (11) : 1445-1455. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035113

Intraductal carcinoma (IC) is the new World Health Organization designation for tumors previously called "low-grade cribriform cystadenocarcinoma" and "low-grade salivary duct carcinoma." The relationship of IC to salivary duct carcinoma is controversial, but they now are considered to be distinct entities. IC is a rare low-grade malignant salivary gland neoplasm with features similar to mammary atypical ductal hyperplasia or ductal carcinoma in situ, that shows diffuse S100 protein and mammaglobin positivity and is only partially defined genetically. (Mammary analogue) secretory carcinoma harboring ETV6-NTRK3, and in rare cases ETV6-RET fusion, shares histomorphologic and immunophenotypical features with IC. Recently, RET rearrangements and NCOA4-RET have been described in IC, suggesting a partial genetic overlap with mammary analogue secretory carcinoma. Here, we genetically characterize the largest cohort of IC to date to further explore this relationship. Seventeen cases of IC were analyzed by next-generation sequencing using the FusionPlex Solid Tumor kit (ArcherDX). Identified fusions were confirmed using fluorescence in situ hybridization break apart and, in some cases, fusion probes, and a reverse transcription polymerase chain reaction designed specifically to the detected breakpoints. All analyzed cases were known to be negative for ETV6 rearrangement by fluorescence in situ hybridization and for ETV6-NTRK3 fusion by reverse transcription polymerase chain reaction. Next-generation sequencing analysis detected a NCOA4-RET fusion transcript joining exon 7 or 8 of NCOA4 gene and exon 12 of RET gene in 6 cases of intercalated duct type IC; and a novel TRIM27-RET fusion transcript between exons 3 and 12 in 2 cases of salivary gland tumors displaying histologic and immunohistochemical features typical of apocrine IC. A total of 47% of IC harbored a fusion involving RET. In conclusion, we have confirmed the presence of NCOA4-RET as the dominant fusion in intercalated duct type IC. A novel finding in our study has been a discovery of a subset of IC patients with apocrine variant IC harboring a novel TRIM27-RET.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035113
003      
CZ-PrNML
005      
20191008095800.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/PAS.0000000000001133 $2 doi
035    __
$a (PubMed)30045065
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Skálová, Alena $u Department of Pathology, Charles University, Faculty of Medicine in Plzen.
245    10
$a Molecular Profiling of Salivary Gland Intraductal Carcinoma Revealed a Subset of Tumors Harboring NCOA4-RET and Novel TRIM27-RET Fusions: A Report of 17 cases / $c A. Skálová, T. Vanecek, E. Uro-Coste, JA. Bishop, I. Weinreb, LDR. Thompson, S. de Sanctis, M. Schiavo-Lena, J. Laco, C. Badoual, T. Santana Conceiçao, N. Ptáková, M. Baněčkova, M. Miesbauerová, M. Michal,
520    9_
$a Intraductal carcinoma (IC) is the new World Health Organization designation for tumors previously called "low-grade cribriform cystadenocarcinoma" and "low-grade salivary duct carcinoma." The relationship of IC to salivary duct carcinoma is controversial, but they now are considered to be distinct entities. IC is a rare low-grade malignant salivary gland neoplasm with features similar to mammary atypical ductal hyperplasia or ductal carcinoma in situ, that shows diffuse S100 protein and mammaglobin positivity and is only partially defined genetically. (Mammary analogue) secretory carcinoma harboring ETV6-NTRK3, and in rare cases ETV6-RET fusion, shares histomorphologic and immunophenotypical features with IC. Recently, RET rearrangements and NCOA4-RET have been described in IC, suggesting a partial genetic overlap with mammary analogue secretory carcinoma. Here, we genetically characterize the largest cohort of IC to date to further explore this relationship. Seventeen cases of IC were analyzed by next-generation sequencing using the FusionPlex Solid Tumor kit (ArcherDX). Identified fusions were confirmed using fluorescence in situ hybridization break apart and, in some cases, fusion probes, and a reverse transcription polymerase chain reaction designed specifically to the detected breakpoints. All analyzed cases were known to be negative for ETV6 rearrangement by fluorescence in situ hybridization and for ETV6-NTRK3 fusion by reverse transcription polymerase chain reaction. Next-generation sequencing analysis detected a NCOA4-RET fusion transcript joining exon 7 or 8 of NCOA4 gene and exon 12 of RET gene in 6 cases of intercalated duct type IC; and a novel TRIM27-RET fusion transcript between exons 3 and 12 in 2 cases of salivary gland tumors displaying histologic and immunohistochemical features typical of apocrine IC. A total of 47% of IC harbored a fusion involving RET. In conclusion, we have confirmed the presence of NCOA4-RET as the dominant fusion in intercalated duct type IC. A novel finding in our study has been a discovery of a subset of IC patients with apocrine variant IC harboring a novel TRIM27-RET.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádorové biomarkery $x analýza $x genetika $7 D014408
650    _2
$a intraduktální neinfiltrující karcinom $x chemie $x genetika $x patologie $7 D002285
650    _2
$a DNA vazebné proteiny $x genetika $7 D004268
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a stanovení celkové genové exprese $x přístrojové vybavení $7 D020869
650    12
$a fúze genů $7 D050939
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a jaderné proteiny $x genetika $7 D009687
650    _2
$a koaktivátory jaderných receptorů $x genetika $7 D056918
650    12
$a sekvenční analýza hybridizací s uspořádaným souborem oligonukleotidů $7 D020411
650    _2
$a fenotyp $7 D010641
650    _2
$a protoonkogenní proteiny c-ret $x genetika $7 D051096
650    _2
$a registrace $7 D012042
650    _2
$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
650    _2
$a nádory slinných žláz $x chemie $x genetika $x patologie $7 D012468
650    _2
$a transkriptom $7 D059467
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Vanecek, Tomas $u Department of Pathology, Charles University, Faculty of Medicine in Plzen. Molecular and Genetic Laboratory, Biopticka Laboratory Ltd, Plzen.
700    1_
$a Uro-Coste, Emmanuelle $u Department of Pathology, Toulouse University Hospital. INSERM U1037, Cancer Research Center of Toulouse (CRCT), Toulouse.
700    1_
$a Bishop, Justin A $u Department of Pathology, UT Southwestern Medical Center, Dallas, TX.
700    1_
$a Weinreb, Ilan $u Department of Pathology, University Health Network, Toronto, ON, Canada.
700    1_
$a Thompson, Lester D R $u Southern California Permanente Medical Group, Woodland Hills, CA.
700    1_
$a de Sanctis, Stefano $u Histopathology Department, Addenbrooke Hospital, Cambridge University Hospitals NHS Trust, Cambridge, UK.
700    1_
$a Schiavo-Lena, Marco $u Department of Pathology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
700    1_
$a Laco, Jan $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine and University Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Badoual, Cécile $u Department of Pathology, G. Pompidou Hospital, Paris, APHP, Paris Descartes University, Paris, France.
700    1_
$a Santana Conceiçao, Thalita $u Department of Oral Pathology, Faculty of Dentistry, University of São Paulo, São Paulo, Brazil.
700    1_
$a Ptáková, Nikola $u Molecular and Genetic Laboratory, Biopticka Laboratory Ltd, Plzen.
700    1_
$a Baněčkova, Martina $u Department of Pathology, Charles University, Faculty of Medicine in Plzen.
700    1_
$a Miesbauerová, Marketa $u Department of Pathology, Charles University, Faculty of Medicine in Plzen.
700    1_
$a Michal, Michal $u Department of Pathology, Charles University, Faculty of Medicine in Plzen.
773    0_
$w MED00000304 $t The American journal of surgical pathology $x 1532-0979 $g Roč. 42, č. 11 (2018), s. 1445-1455
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30045065 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191008100216 $b ABA008
999    __
$a ok $b bmc $g 1451773 $s 1073663
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 42 $c 11 $d 1445-1455 $e - $i 1532-0979 $m The American journal of surgical pathology $n Am J Surg Pathol $x MED00000304
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Možnosti archivace